Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2006

View Archived Issues

Incyte presents highlights of quarter

Taligen achieves Series A milestone with in vivo efficacy of TA-106

IVI to study CholeraGarde in funded program

SPA agreement for phase II study of pralatrexate in peripheral T-cell lymphoma

Neuren selects new compound for Parkinson's disease

Successful end of phase II meeting for cetilistat

Abuse-resistant opioid PTI-202 begins clinical testing

ISTA inlicenses North American rights to ophthalmic bepotastine

V-3381 studied in phase IIa trial for diabetic neuropathic pain

Advate receives Health Canada approval

Competact receives European approval for diabetes

AEterna Zentaris licenses ozarelix to Nippon Kayaku in Japan

Sphingosome encapsulated vinorelbine studied in advanced solid tumors

Sitagliptin begins phase III diabetes studies in Japan

Ceftaroline shows excellent clinical, microbiological cure rates for cSSSI

Terlipressin fails to meet primary endpoint in type 1 hepatorenal syndrome study

Ozarelix dosage regimen identified for continuous suppression of testosterone

Novel amidine analogue of melphalan exhibits more potent cytotoxicity in breast cancer cell lines

New antidiabetic agents disclosed in recent patent literature

New compounds with potential use in cancer treatment covered in recent patent literature

Recent patents describe novel agents for obesity, hypercholesterolemia, etc.

Betaseron approved in Canada for earliest stages of MS

Antidote for isotope intoxication reported by Department of Atomic Energy in India

Targeting 5-HT6 receptors with E-6837: a novel approach for the management of obesity

Novel CB1 receptor antagonist shows antiobesity potential in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...